September 15, 2017
News & Publications
Press Releases
September 5, 2017
H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer
Read More »
August 14, 2017
H3 Biomedicine Granted Orphan Drug Designation of H3B-8800 for Treatment of Acute Myelogenous Leukemia and Chronic Myelomonocytic Leukemia
Read More »
July 24, 2017
H3 Biomedicine and University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer
Article published in current issue of Nature Communications details that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion… Read More »
June 1, 2017
H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research around Splicing Modulators Published in Current Issue of Nature Communications
Read More »
May 1, 2017
H3 Biomedicine Appoints Lihua Yu, Ph.D., to Chief Data Sciences Officer
Read More »In the Media
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More »
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More »
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »
FasterCures
Fixes in Financing
High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More »Scientific Publications
Nature Communications
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority… Read More »
Nature Communications
Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex
Pladienolide, herboxidiene and spliceostatin have been identified as splicing modulators that target SF3B1 in the SF3b subcomplex. Here we report… Read More »
Cancer Cell
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
Mutations in SF3B1, which encodes a spliceosome component, are associated with poor outcome in chronic lymphocytic leukemia (CLL), but how… Read More »
Leukemia
Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts
Heterozygous somatic mutations affecting the spliceosome gene SF3B1 drive age-related clonal hematopoiesis, myelodysplastic syndromes (MDS) and other neoplasms. Read More »Media Inquiries
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Paul Kidwell.
